Notably, exclusion of the recurrent “unreliable” SHFM4/EEC3 mutation R337Q yielded a refined SHFM4 cohort (n = 137 for triad symptoms; n = 125 for ectodermal sub‐phenotypes) showing modified profiles: the overall ectodermal dysplasia frequency decreased to 23% (32/137), where tooth (18%), hair (14%), skin (11%) and nail (10%) abnormalities predominated, and lacrimal gland (3%)/breast (0%) involvement became negligible. The gene discussed is TP63; the disease is ectodermal dysplasia syndrome.